Fig. 7
Testing tumor growth kinetics and immunotherapy response in immunodeficient and EMT6 murine models. Tumors from the autochthonous MMTV-PyMT model were harvested and single-cell suspensions were generated. a CD45+ cells were successfully removed (“sorted”). b Cells (1E6, 1E5, or 1E4) were injected into the mammary fat pad of FVB/NJ wild-type or nude mice. c-d Tumor volumes were measured and plotted as the mean total tumor burden ± SEM and the survival of nude mice are shown (d). e When the tumors reached 100 mm3, mice were randomized to treatment with Vehicle (IgG2B) or the combination of anti-PD-L1 plus anti-CTLA-4. f–g Babl/c mice were implanted with 1E6 or 1E4 tumor cells, and tumor growth kinetics (f) and response to vehicle and combination of anti-PD-L1 plus anti-CTLA-4 (g) were plotted. Tumor volumes were measured and plotted as the mean total tumor burden ± SEM. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001